Role in Tumor Cell Survival

Role of EGFR in healthy cells in metastatic non-small cell lung cancer (NSCLC)
Role of EGFR in healthy cells in metastatic non-small cell lung cancer (NSCLC)

EGFR is a cell membrane receptor1

In healthy cells, EGFR plays an integral role in multiple biological processes, including proliferation, gene expression, survival, and apoptosis.1

EGFR mutations may lead to increased signaling in metastatic non-small cell lung cancer (NSCLC)
EGFR mutations may lead to increased signaling in metastatic non-small cell lung cancer (NSCLC)

At diagnosis: sensitizing EGFR mutations

Mutations in EGFR may lead to increased signaling1,2

EGFR activity may be dysregulated through various mechanisms, including sensitizing mutations that affect tyrosine kinase activity and lead to constitutive activation.1,2

Inhibiting EGFR may slow tumor growth in metastatic non-small cell lung cancer (NSCLC)
Inhibiting EGFR may slow tumor growth in metastatic non-small cell lung cancer (NSCLC)

Targeted therapies can inhibit EGFR signaling1

Inhibiting EGFR may slow tumor cell growth.1

Upon disease progression: EGFR resistance mutations

Patients treated with 1st- or 2nd-generation EGFR-TKIs may develop resistance mutations.3

 

Resistance via an acquired mutation is the most common mechanism of progression3

 

Acquired resistance mutations can lead to progression in metastatic non-small cell lung cancer (NSCLC)
Acquired resistance mutations can lead to progression in metastatic non-small cell lung cancer (NSCLC)

 

Acquired drug resistance may be initiated by clones with mutations that confer a survival advantage under the selective pressure of an EGFR-TKI.3

 

EGFR, epidermal growth factor receptor; NSCLC, non–small cell lung cancer; TKI, tyrosine kinase inhibitor.

References: 1. Baselga J. Oncologist. 2002;7(suppl 4):2-8. 2. Sharma SV et al. Nat Rev Cancer. 2007;7(3):169-181. 3. Sacher AG et al. Cancer. 2014;120(15):2289-2298.